Sientra Inc. (SIEN) Upgraded to “Hold” by Zacks Investment Research
Sientra Inc. (NASDAQ:SIEN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
Separately, William Blair reaffirmed a “market perform” rating on shares of Sientra in a research note on Wednesday, August 10th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $28.50.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/sientra-inc-sien-upgraded-to-hold-by-zacks-investment-research-2.html
Sientra (NASDAQ:SIEN) opened at 8.40 on Wednesday. Sientra has a 12 month low of $2.78 and a 12 month high of $20.63. The firm’s market cap is $152.33 million. The stock has a 50 day moving average of $7.98 and a 200-day moving average of $7.25.
Sientra (NASDAQ:SIEN) last announced its earnings results on Tuesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by $0.05. The company earned $6.20 million during the quarter, compared to analysts’ expectations of $4.80 million. Sientra had a negative net margin of 297.09% and a negative return on equity of 36.16%. Equities research analysts predict that Sientra will post ($2.31) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp boosted its position in shares of Sientra by 23.9% in the first quarter. State Street Corp now owns 82,717 shares of the company’s stock worth $563,000 after buying an additional 15,954 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Sientra by 67.5% in the first quarter. Geode Capital Management LLC now owns 71,919 shares of the company’s stock worth $491,000 after buying an additional 28,980 shares during the last quarter. TIAA CREF Investment Management LLC acquired a new position in shares of Sientra during the first quarter worth approximately $253,000. Paloma Partners Management Co acquired a new position in shares of Sientra during the second quarter worth approximately $198,000. Finally, Cannell Capital LLC boosted its position in shares of Sientra by 95.2% in the second quarter. Cannell Capital LLC now owns 855,997 shares of the company’s stock worth $5,632,000 after buying an additional 417,364 shares during the last quarter. Institutional investors and hedge funds own 68.85% of the company’s stock.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.